Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study
Version of Record online: 15 JAN 2009
© 2009 The Authors. Journal compilation © 2009 Japanese Society of Psychiatry and Neurology
Psychiatry and Clinical Neurosciences
Volume 63, Issue 1, pages 73–81, February 2009
How to Cite
Kwon, J. S., Jang, J. H., Kang, D.-H., Yoo, S. Y., Kim, Y. K., Cho, S.-J. and the APLUS study group (2009), Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study. Psychiatry and Clinical Neurosciences, 63: 73–81. doi: 10.1111/j.1440-1819.2008.01907.x
- Issue online: 15 JAN 2009
- Version of Record online: 15 JAN 2009
- Received 18 February 2008; revised 9 September 2008; accepted 22 September 2008.
- 77-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H) -qui nolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J. Pharmacol. Exp. Ther. 1995; 274: 329–336., , et al.
- 13American Psychiatric Association. American Psychiatric Association. Task Force on DSM-IV. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. American Psychiatric Association, Washington, DC, 1994.
- 15ECDEU Assessment Manual for Psychopharmacology. U.S. Department of Health, Education, and Welfare, Public Health Service (ADM), Rockville, MD, 1976., United States National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, George Washington University, Biometric Laboratory.